The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Tils is a Giant compared to sng.
That's why chief medical officer.from Regeneron chose to come to tils.
It's like man utd v Accrington Stanley.
TILS being man utd.
The race to 300 is still on ....
May the best team win :-)
Tils was valued at 700 million
stunning volume
Volume 19,463,902
Avg. Volume 522,485
If the numbers look the same or better in the morning TILS might find itself in the FTSE 250? How exciting.
There will almost certainly be an RNS tomorrow which keeps in line with the usual Tiziana starategy of announcements e.g. formalising their plans and then releasing more info as and when they happen.
Can only see more rising ahead tomorrow as we bid farewell to the roller coaster AIM and arrive on the steady 'serious' main market, more belonging to a company of TILS stature and potential. Good weeks ahead for us holders. Honest target of 320p for myself
Wasn't only the Americans! ;-)
US - Trading @£1.75 as they should be.
Main market listings will hopefully trade in unison
BB
Depends entirely on circumstance
This to me says Rns tomorrow morning to go along with listing on main market
W0W nearly 20 million shares traded. Surely that has sweet FA to do with market listing this side? Must be a pre- RNS leak??
Sorry mate I hadn’t realised u had posted that link
So with TLSA being 47% up in 1 day would it of been worth selling and switching to the nasdaq?
Hoping for a huge increase in the morning now so they can keep chasing us :)
Credit to the main man Astro for finding this tweet from Dr kunwar who seems to be implying to me at least ,that maybe the treatment we are providing in the Brazil trial may just be the answer to combating the new South African strain of the virus ...which the new vaccines appears to be struggling with ... if so ...that’s proper start the car time here GLA
https://twitter.com/astrobrook/status/1351995399893086209?s=21
I believe the main market will do us a lot of good.
Upward trend from here.
45% up on nasdaq atm
Think big, we are with the big boys now.
Foralumab is the world’s first and only, fully human anti-CD3 antibody and can be delivered orally, making it a potential game changer in the treatment of Crohn’s Disease and other autoimmune diseases through higher efficacy and reduced toxicity.
Foralumab modulates the immune response, reducing inflammation locally and systemically, through interaction with the gastrointestinal and nasal mucosal immune system.
Market opportunities....
COVID
NASH
RA
PSORIASIS
LUPUS
MS
IBD
GVHD
Remember many of these conditions are treat via IV... We will offer nasal and oral option.... Less side effects... Reduced costs!
Forget covid.... Look at the market we can tap into... We only need one.
I guess for the Americans it's the last chance for them to get in... If we get an rns tommorow... Atleast on the nasdaq anyway.
..well overdue...
Holding strong
GL
Hi Whimax
currently + 53%
Depends really. Moving out of ISA and then paying charges and tax may have not been worth it
TLSA heading back to $5 now.
Why not..... Valuations for tils without accustem were 8 dollars to 11 dollars with buy ratings.
Which is 290p to 400p...... I'd say the estimates were also on the low side... So who knows even higher.
All I know is... Anything under 200p is still very cheap for what TILS has on offer.
TOPLINE covid results imminent.... From today's breakout something good must be coming